Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 09, 2022 03:00 ET | Source: Core One Labs Inc.

Core One Labs’ Successful Patent Application Filing for Protection of its Biosynthetic Production System for Psilocybin Marks a Significant Milestone for the Progression of Psychedelic Health Care

VANCOUVER, British Columbia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that...
July 26, 2021 07:00 ET | Source: Core One Labs Inc.

Core One Labs’ Akome Seeks to Revolutionize Treatment of Parkinson’s Disease and Submits Application to Protect IP

VANCOUVER, British Columbia, July 26, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (the “Company”) is pleased to announce that its wholly...
July 21, 2021 03:00 ET | Source: Core One Labs Inc.

Core One Labs’ Akome Biotech Protects New AKO003 Ketamine-Based Breakthrough Drug Formulation For Depression Treatment

VANCOUVER, British Columbia, July 21, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL) (OTC: CLABD) (Frankfurt: LD6, WKN:A3CSSU) (the “Company”) is excited to announce that its wholly owned...
June 21, 2021 09:15 ET | Source: Core One Labs Inc.

REPEAT - New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed

VANCOUVER, British Columbia, June 21, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce that its wholly...
June 19, 2021 18:30 ET | Source: Core One Labs Inc.

New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed

VANCOUVER, British Columbia, June 19, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce that its wholly...
May 06, 2021 09:00 ET | Source: Core One Labs Inc.

REPEAT – Core One Labs Commences Development on Patent Pending Psychedelic Drug Formulation for the Treatment of Alzheimer’s Disease

VANCOUVER, British Columbia, May 06, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) is pleased to announce that...
May 06, 2021 03:10 ET | Source: Core One Labs Inc.

Core One Labs Commences Development on Patent Pending Psychedelic Drug Formulation for the Treatment of Alzheimer’s Disease

VANCOUVER, British Columbia, May 06, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) is pleased to announce that...
May 04, 2021 09:00 ET | Source: Core One Labs Inc.

REPEAT - Core One Labs Completes Milestone Acquisition of Akome Biotech

VANCOUVER, British Columbia, May 04, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) a biotechnology research and...
May 04, 2021 03:10 ET | Source: Core One Labs Inc.

Core One Labs Completes Milestone Acquisition of Akome Biotech

VANCOUVER, British Columbia, May 04, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) a biotechnology research and...
April 29, 2021 09:00 ET | Source: Core One Labs Inc.

REPEAT -- Core One Labs Reaches Definitive Agreement to Acquire Akome Biotech

VANCOUVER, British Columbia, April 29, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”), a biotechnology research and development...

Next Page keyboard_arrow_right